BioMérieux has announced that it will phase out activities at its Boxtel site in the Netherlands by the end of 2009.
The site develops and manufactures reagents for molecular biology and immunoassay microplate product lines.
The French-based company provides diagnostic solutions (reagents, instruments and software) which determine the source of disease and contamination.
In a statement, the company said it remained committed to developing and supporting the products currently manufactured at Boxtel, recognising the important role they played in public
health.
Information on the transfer of current activities from Boxtel to other locations would be communicated at a later date.
Some 287 employees are understood to work at the Boxtel site.
The company has said it will make every effort to support employees through this period.
